ArticleClinical interventions in aging2025
Enhanced Recovery After Surgery (ERAS) Program for InterTAN Nail Surgery in Intertrochanteric Femoral Fracture (ITF) Patients Over 75 years Old.
Article in Clinical interventions in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Enhanced Recovery After Surgery (ERAS) has been extensively applied across numerous surgical specialties. However, there remains a paucity of research regarding the implementation of ERAS in advanced age patients (≥75 years) who undergo InterTAN nail surgery for intertrochanteric femoral fractures (ITF). This study aimed to assess if our ERAS protocol improves satisfaction and clinical outcomes in such patients. Methods: This was a retrospective cohort study included advanced age patients who underwent InterTAN nail surgery. The ERAS group included patients who underwent surgery between January 2022 and December 2024, while the non - ERAS group consisted of those who had the same surgery between January 2019 and December 2023. Demographics, comorbidities, surgical details, ERAS compliance, outcomes, complications, and length of stay (LOS) were evaluated. Results: A total of 144 patients were included in the ERAS group and 135 in the non - ERAS group. Analysis of demographic data showed no statistically significant intergroup differences. ERAS compliance was 100%. There were no significant differences between the ERAS and non - ERAS groups in terms of operative side, anesthesia type, operating time, intraoperative blood loss, and postoperative Visual Analogue Scale scores. Moreover, 30 - day follow - up revealed no significant differences in readmission rates and mortality between the two groups. However, the LOS was significantly shorter in the ERAS group (5.68±2.34 days vs 6.54±2.04 days in the non - ERAS group; p = 0.03). The overall complication rate was also significantly lower in the ERAS group (10/144 vs 23/135; P < 0.01). Conclusion: In this cohort of advanced age patients with ITF managed via our ERAS program, it was evidenced that this program is safe and can effectively reduce the LOS and the incidence of complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.